The ISDE 2021 World Congress is a wrap! Today was the final day of the 17th congress, covering 3 streams of concurrent content for 4 hours over 4 days.
Posters and presentations will be available for streaming for 6 months, using your registration log-in.
New live webinar: October 12, 2021, 13:00-14:30 GMT
Join an international panel of speakers for a virtual presentation devoted to registries and audits in esophagogastric cancer surgery. A series of registries from all around the world are presented with their set-up, results and effect on national or regional outcomes and the way research is incorporated into these registries.
Defining Quality of Care in Esophagogastric Cancer Surgery
Patient Reported Outcomes in Auditing. What can we learn from them? Is it the future?
What is the Future of Research Within Registries?
Registries and Audits: Learning from Current Nationwide Experiences
See the videos from the last virtual presentation in which the speakers discussed opioid induced esophageal dysfunction, non-achalasia spastic disorders (jackhammer, distal esophageal spasm), and hypomotility disorders (ineffective esophageal motility and esophageal aperistalsis). Watch the recordings here.
Go through the ISDE 2021 Congress Supplement. Abstracts submitted to the 17th ISDE World Congress for Esophageal Diseases are now available online. See the full table of contents.
The laparoscopic part of minimal invasive esophagectomy (MIE) and gastric pull-up has become the preferred approach either in hybrid or total MIE. The advantages are well known, however, one shortcoming is the increased rate of postoperative paraconduit hiatal hernias (PHH) leading to enterothorax. Read the full article.
Surgery for benign esophageal diseases may be complex, requiring specialist training, but currently, unlike oncologic surgery, it is not centralized. The aim of the study was to explore the opinion of European surgeons on the centralization of surgery for benign esophageal diseases. A web-based questionnaire, developed through a modified Delphi process, was administered to general and thoracic surgeons. Read the full article.
Chylothorax has been reported to occur at rates of 0.4% for all general thoracic surgery procedures and 4.7–8.6% after esophagectomy. The conservative treatment with fat-free diet, parenteral nutrition, somatostatin/octreotide has very limited results. Surgical treatment success rates are as high as 91%, but with high morbidity and mortality rates. Minimally invasive, percutaneous treatment was developed as an alternative treatment, with low morbidity and mortality rates. In this study of Bazancir et al, report 88, 2% clinical success rates for Thoracic Duct Embolization. It is a procedure which is highly operator dependent, with other studies showing much smaller success rates, but in high-volume esophagectomy groups, should be considered as an alternative to more aggressive treatments. Read the full article.
